Daytrana
Links shared publicly online about this topic
Daytrana patches recalled by Shire - MPR
empr.com — “Shire is voluntarily recalling five lots and withdrawing one lot of Daytrana (methylphenidate transdermal system) due to difficulty removing the release liner from some of the patches.” View full resource at empr.com
Most Recently Shared on December 3, 2009 at 4:58 pm By:
MPR News: Daytrana patches recalled by Shire: Shire is voluntarily recalling five lots and withdrawing one lot of D... http://bit.ly/6nkaAK
Shire issues recall of Daytrana patches - MPR
empr.com — “Shire has issued a voluntary recall of 39 lots of Daytrana (methylphenidate) transdermal patches because of difficulties removing the release liner.” View full resource at empr.com
Most Recently Shared on March 20, 2009 at 3:45 pm By:
Shire issues recall of Daytrana patches : Shire has issued a voluntary recall of 39 lots of Daytrana (methylphen.. http://tinyurl.com/cgh3wa
Shire announces divestiture of Daytrana to Noven Pharmaceuticals
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.” View full resource at news-medical.net
Most Recently Shared on August 11, 2010 at 4:46 pm By:
Stroke News: Shire announces divestiture of Daytrana to Noven Pharmaceuticals: Shire plc, the global specialty b... http://twurl.nl/20p7k8
Shire announces Phase IIIb study results of Daytrana
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).” View full resource at news-medical.net
Most Recently Shared on October 31, 2009 at 10:11 am By:
Stroke News: Shire announces Phase IIIb study results of Daytrana: Shire plc, the global specialty .. http://twurl.nl/ry1u35
Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents - MPR
empr.com — “The FDA has approved Daytrana (methylphenidate transdermal system, from Shire) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents 13"17 years of age.” View full resource at empr.com
Most Recently Shared on July 7, 2010 at 3:13 pm By:
MPR News: Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents: The FDA ha... http://bit.ly/boPPmm
Noven acquires global rights to Daytrana from Shire affiliates
news-medical.net — “Noven Pharmaceuticals, Inc. today announced that it has completed the acquisition of global rights to Daytrana® (methylphenidate transdermal system) from affiliates of Shire plc.” View full resource at news-medical.net
Most Recently Shared on October 1, 2010 at 2:20 pm By:
Noven acquires global rights to Daytrana from Shire affiliates: Noven Pharmaceuticals, Inc. today announced that i... http://bit.ly/dpepvb
Shire receives FDA approval of Daytrana for ADHD in adolescents
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include ” View full resource at news-medical.net
Most Recently Shared on July 7, 2010 at 5:40 am By:
Shire receives FDA approval of Daytrana for ADHD in adolescents: Shire plc, the global specialty biopharmaceutical... http://bit.ly/atTr4s
FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
drugs.com — “Daytrana (methylphenidate) is used for attention deficit hyperactivity disorder. Information from Drugs.com includes Daytrana side effects, interactions, indications” View full resource at drugs.com
Most Recently Shared on July 8, 2010 at 7:20 pm By:
FDA Approves Daytrana for the Treatment of ADHD in Adolescents - http://bit.ly/aZ1hIE
Noven Completes Acquisition of Daytrana Methylphenidate Transdermal System (CII) from Shire - Drugs.com MedNews
drugs.com — “First and Only Patch for ADHD Now to be Marketed and Sold by Noven Therapeutics Oct 1, 2010 - Noven Pharmaceuticals, Inc. today announced that it has completed” View full resource at drugs.com
Most Recently Shared on October 1, 2010 at 4:19 pm By:
Drugs and Devices OW OW Health
Noven Completes Acquisition of Daytrana Methylphenidate Transdermal System (CII) from Shire: First and Only P... http://bit.ly/9YGHxH #drug
Shire To Divest Brain Stimulator Daytrana To Noven Pharma; Maintains FY10 Earnings View
rttnews.com — “Specialty biopharmaceutical company Shire plc, Tuesday announced the divestiture of its brain stimulant medicine Daytrana to Noven Pharmaceuticals, Inc., granting Noven global marketing rights for the medicine, effective October 1, 2010.” View full resource at rttnews.com
Most Recently Shared on August 11, 2010 at 3:09 am By:
Peter H Brown Doctor and Psychologist
Shire To Divest Brain Stimulator Daytrana To Noven Pharma; Maintains FY10 ... http://bit.ly/ahRdPa #ADHD
Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug? | BNET Pharma Blog | BNET
industry.bnet.com — “Shire (SHPGY) has voluntarily recalled the Daytrana ADHD patch citing problems with patients removing the liner on the back. It is not a safety issue,” View full resource at industry.bnet.com
Most Recently Shared on December 7, 2009 at 4:49 pm By:
Jim Edwards Health Communicator
Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug?: Shire (SHPGY) has voluntarily recalled the Day... http://bit.ly/5d1A9H
Study Findings On ADHD Treatments Presented At Psychiatric Meeting
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) t” View full resource at medicalnewstoday.com
Most Recently Shared on October 30, 2009 at 3:59 pm By:
MNT Psychology News Health News
Study Findings On ADHD Treatments Presented At Psychiatric Meeting: Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl.. http://bit.ly/2g2hjD
Study Findings On ADHD Treatments Presented At Psychiatric Meeting
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) t” View full resource at medicalnewstoday.com
Most Recently Shared on October 30, 2009 at 3:30 pm By:
psychiatryrounds Support and Psychiatry
Study Findings On ADHD Treatments Presented At Psychiatric Meeting: Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl.. http://bit.ly/tDMfR
ADHD News
healthcentral.com — “Get the latest breaking news and research on ADHD.” View full resource at healthcentral.com
Most Recently Shared on June 30, 2010 at 8:32 pm By:
How to handle my child with adhd - ADHD
healthcentral.com — “My 8 yr. old daughter has adhd, and took concerta for about 4 months. She was switched to daytrana. I am having a really hard time with disciplining her. I can'...” View full resource at healthcentral.com
Most Recently Shared on July 28, 2011 at 3:51 pm By:
HealthCentral Tips Health Site
@abnormalpsy55 What are your trips for handling a child with ADHD? @eileenmbailey share her tips about kids and ADHD: http://bit.ly/q48k0U
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
News-Medical.Net
Stay up to date with the latest Stroke news and research via News-Medical.Net
Advertisement
